PROTAC targeted protein degraders: the past is prologue

por Békés, Miklós, Langley, David R., Crews, Craig M.
Publicado 2022

Mechanistic Characterization and Molecular Modeling of Hepatitis B Virus Polymerase Resistance to Entecavir

por Walsh, Ann W., Langley, David R., Colonno, Richard J., Tenney, Daniel J.
Publicado 2010

Mutagenic Activation of Glutathione Peroxidase-4: Approaches toward Rational Design of Allosteric Drugs

por Ma, Chunyue, Chung, Daniel J., Abramson, Dylan, Langley, David R., Thayer, Kelly M.
Publicado 2022

The crystal structure of NS5A domain 1 from genotype 1a reveals new clues to the mechanism of action for dimeric HCV inhibitors

por Lambert, Sebastian M, Langley, David R, Garnett, James A, Angell, Richard, Hedgethorne, Katy, Meanwell, Nicholas A, Matthews, Steve J
Publicado 2014

Homology models of the HIV-1 attachment inhibitor BMS-626529 bound to gp120 suggest a unique mechanism of action

por Langley, David R, Roy Kimura, S, Sivaprakasam, Prasanna, Zhou, Nannan, Dicker, Ira, McAuliffe, Brian, Wang, Tao, Kadow, John F, Meanwell, Nicholas A, Krystal, Mark
Publicado 2015

Lattice engineering enables definition of molecular features allowing for potent small-molecule inhibition of HIV-1 entry

por Lai, Yen-Ting, Wang, Tao, O’Dell, Sijy, Louder, Mark K., Schön, Arne, Cheung, Crystal S. F., Chuang, Gwo-Yu, Druz, Aliaksandr, Lin, Bob, McKee, Krisha, Peng, Dongjun, Yang, Yongping, Zhang, Baoshan, Herschhorn, Alon, Sodroski, Joseph, Bailer, Robert T., Doria-Rose, Nicole A., Mascola, John R., Langley, David R., Kwong, Peter D.
Publicado 2019

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

por Gao, Min, Nettles, Richard E., Belema, Makonen, Snyder, Lawrence B., Nguyen, Van N., Fridell, Robert A., Serrano-Wu, Michael H., Langley, David R., Sun, Jin-Hua, O’Boyle II, Donald R., Lemm, Julie A., Wang, Chunfu, Knipe, Jay O., Chien, Caly, Colonno, Richard J., Grasela, Dennis M., Meanwell, Nicholas A., Hamann, Lawrence G.
Publicado 2010

Crystal structures of trimeric HIV Env with entry inhibitors BMS-378806 and BMS-626529

por Pancera, Marie, Lai, Yen-Ting, Bylund, Tatsiana, Druz, Aliaksandr, Narpala, Sandeep, O’Dell, Sijy, Schön, Arne, Bailer, Robert T., Chuang, Gwo-Yu, Geng, Hui, Louder, Mark K., Rawi, Reda, Soumana, Djade I., Finzi, Andrés, Herschhorn, Alon, Madani, Navid, Sodroski, Joseph, Freire, Ernesto, Langley, David R., Mascola, John R., McDermott, Adrian B., Kwong, Peter D.
Publicado 2017